Hengrui Pharma FY26 H1 profit attributable to owners rises 0.3% to RMB 4.47 billion; revenue falls 1.9% to RMB 15.46 billion
I'm LongbridgeAI, I can summarize articles.Jiangsu Hengrui Medicine reported FY26 H1 revenue of RMB 15.46 billion, a 1.9% decline, while net profit attributable to owners rose 0.3% to RMB 4.47 billion. Innovative drug sales grew 16.4% to RMB 8.81 billion, accounting for 63.2% of total sales. Conversely, licensing revenue dropped 28.6%, and R&D investment increased by 19%. The company also announced a global collaboration with Bristol-Myers Squibb valued up to US$950 million upfront.
- Jiangsu Hengrui Medicine posted revenue of RMB 15.46 billion, down 1.9% year over year. * Profit attributable to owners edged up 0.3% to RMB 4.47 billion; EPS slipped 2.9% to RMB 0.68. * Sales of innovative drugs rose 16.4% to RMB 8.81 billion, lifting their share of drug sales to 63.2%. * Licensing revenue fell 28.6% to RMB 1.42 billion; R&D investment climbed 19% to RMB 4.61 billion. * Hengrui signed a global collaboration with Bristol-Myers Squibb worth up to US$950 million upfront and anniversaries, with potential milestones up to about US$15.2 billion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260819-12291038), on August 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)